Zabedosertib clinical trials
Also written BAY1834845.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses zabedosertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BAY1834845
- 4
Studies by the year they started
5 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses zabedosertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic DermatitisCompletedPhase 2BayerNCT05656911Written as Zabedosertib (BAY1834845)
- A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male ParticipantsCompletedPhase 1BayerNCT05003089Written as BAY1834845
- A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With PsoriasisCompletedPhase 1BayerNCT03493269Written as BAY1834845
- Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With MethotrexateCompletedPhase 1BayerNCT03244462Written as BAY1834845
- First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845CompletedPhase 1BayerNCT03054402Written as BAY1834845
Codes
What other systems call zabedosertib · ClinicalTrials.gg INT001994
- MeSH (NLM) C000723917zabedosertibOne source NLM
- UNII (FDA) N1GRK350ZMZABEDOSERTIBConfirmed FDA, NLM
- NCI Thesaurus C179134ZabedosertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723917 | zabedosertib | One source NLM |
| UNII (FDA) | N1GRK350ZM | ZABEDOSERTIB | Confirmed FDA, NLM |
| NCI Thesaurus | C179134 | Zabedosertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.